Update on Progress in Katalysen's Venture Targeter
Katalysen’s portfolio company Venture Targeter AB ("Venture Targeter") recently announced its inaugural investment into biotech company QuTEM (formerly Vironova BioAnalytics). Readers will find a more detailed presentation (PDF) attached with this press release.Venture Targeter, established by Katalysen Ventures AB (publ) (“Katalysen”), is dedicated to identifying, structuring, and executing special situation investments in collaboration with co-investors and industry experts. Specializing in distressed assets and the turnaround of companies to maximize value extraction, Venture Targeter